23 citations
,
September 2017 in “Journal of the American Academy of Dermatology” Apremilast did not work for treating severe alopecia areata.
9 citations
,
April 2018 in “Journal of Dermatological Treatment” Tofacitinib improves nail conditions in patients with severe hair loss and does not affect hair regrowth.
February 2026 in “Frontiers in Immunology” Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib significantly regrows hair in teens with severe alopecia areata.
June 2024 in “Dermatology and Therapy” Baricitinib improves quality of life and reduces anxiety and depression in severe alopecia areata patients with hair regrowth.
Baricitinib shows promise for treating alopecia areata with mild side effects.
196 citations
,
September 2016 in “JCI insight” Ruxolitinib effectively regrows hair in most patients with severe hair loss.
20 citations
,
January 2013 in “Evidence-based complementary and alternative medicine” TGPC plus CGT is effective and safe for treating severe alopecia areata in children.
4 citations
,
July 2020 in “Journal of Dermatological Treatment” Minoxidil injections can speed up hair regrowth in non-severe patchy hair loss, but combining it with steroids doesn't improve results.
March 2022 in “Nepal Journal of Dermatology Venereology & Leprology” Methotrexate with steroids is slightly more effective than azathioprine with steroids for treating severe alopecia areata.
May 2015 in “Journal of The American Academy of Dermatology” Both treatments help with hair regrowth in alopecia areata, but azathioprine has milder side effects than betamethasone.
18 citations
,
March 2014 in “Drug Development and Industrial Pharmacy” New gel formulas without ethanol and propylene glycol, containing a minoxidil-methyl-β-cyclodextrin complex, have been created for treating hair loss.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib helps regrow scalp, eyebrow, and eyelash hair in teens with severe alopecia areata.
April 2024 in “Frontiers in medicine” Alopecia Areata significantly lowers quality of life and current treatments are inadequate, highlighting a need for better therapies and standardized treatment protocols.
December 2025 in “Clinical Cosmetic and Investigational Dermatology” Early diagnosis and multidisciplinary care, including orthopedic surgery, can prevent long-term disability in IFAP syndrome.
10 citations
,
January 2013 in “International Journal of Trichology” Systemic steroids effectively treated severe nail issues in a card illusionist with alopecia areata.
July 2014 in “Journal of Dermatology” Educating patients on phototrichogram increased satisfaction in androgenetic alopecia treatment.
August 2025 in “American Journal of Clinical Dermatology” Clinicians should use evidence-based tools and consider mental health when assessing alopecia areata to guide treatment.
January 2025 in “International Journal of Dermatology Sciences” Nail changes in alopecia areata are common and may indicate severity and genetic risk.
June 2022 in “Value in Health” Adding Baricitinib for severe alopecia areata will have a small impact on a health plan's budget.
13 citations
,
September 2018 in “Journal of the American Academy of Dermatology” The document concludes that a new system using the SALT score should replace the current alopecia areata classification for better accuracy in assessing severity and prognosis.
November 2023 in “International Journal of Dermatology” Trichoscopy helps tell apart other hair loss conditions from common hair loss.
12 citations
,
January 2011 in “Photodermatology, photoimmunology & photomedicine” This therapy effectively treats resistant alopecia areata with minimal side effects.
11 citations
,
November 2019 in “Journal of the American Academy of Dermatology” Oral tofacitinib is a promising treatment for beard hair loss in alopecia areata.
10 citations
,
January 2023 in “Acta dermato-venereologica” Baricitinib and deuruxolitinib are effective for treating alopecia areata, but their efficacy depends on the dose.
January 2026 in “Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna)” Baricitinib effectively promotes hair regrowth and improves well-being in severe alopecia areata patients.
November 2025 in “Turkish Journal of Dermatology” Both baricitinib and tofacitinib effectively reduce alopecia areata severity, with tofacitinib showing more improvement over longer use.
November 2023 in “Indian Dermatology Online Journal” Tofacitinib was effective for severe, treatment-resistant hair loss without side effects.
Topical calcipotriol successfully treated hair loss in three patients with Alopecia Totalis.
36 citations
,
May 2005 in “BMC dermatology” DPCP is effective for treating severe alopecia areata, but relapse is common.